



1/31

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Craig A. Coburn et al.	
Serial No.:	10/541,476	Case No.: 21310YP
Filed:	July 6, 2005	
For:	MACROCYCLIC BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	


Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to:
Commissioner for Patents, P. O. Box 1450,
Alexandria, VA 22313-1450, on the date appearing Below.

MERCK & CO., INC.
By  Date 1-26-2006

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 
John C. Todaro, Reg. No. 36,036
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0125

Date: January 26, 2006

COMPLETE IF KNOWN

Application Number	10/541,476
Filing Date	July 6, 2005
First Named Inventor	Craig A. Coburn et al.
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	21310YP

(use as many sheets as necessary)

1

of

3

Attorney Docket Number 21310YP

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	A		WO 89/04833		The Upjohn Company	06/01/1989
	B		WO 01/00665		Oklahoma Medical Research Foundation	01/04/2001
					and The Board of Trustees of the	
					University of Illinois	
	C		WO 2003/072535		Elan Pharmaceuticals, Inc.	09/04/2003
	D		EP 1 186 305		Schering Aktiengesellschaft	03/13/2002
	E		WO 02/02512		Elan Pharmaceuticals, Inc. /Pharmacia &	01/10/2002
					Upjohn Company	
	F		WO 03/257721		Elan Pharmaceuticals, Inc. /Pharmacia &	07/17/2003
					Upjohn Company	

Date
Considered

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

COMPLETE IF KNOWN

Application Number	10/541,476
---------------------------	------------

Filing Date	July 6, 2005
--------------------	--------------

First Named Inventor	Craig A. Coburn et al.
-----------------------------	------------------------

Group Art Unit	To Be Assigned
----------------	----------------

Examiner Name	To Be Assigned
---------------	----------------

Attorney Docket Number 21310YP

2

of.

3

Examiner
Initials*Cite
No.

U.S. Patent Document

Number

Kind
Code
(if known)Name of Patentee or Applicant
of Cited Document

Date of Publication of
Cited Document
MM-DD-YYYY

Examiner
Initials*Cite
No.

Foreign Patent Document

Office

Number

Kind
Code
(if known)Name of Patentee or Applicant
of Cited Document

Date of Publication of
Cited Document
MM-DD-YYYY

G

WO 02/100399

Elan Pharmaceuticals, Inc./Pharmacia &
Upjohn Company

12/19/2002

H

WO 02/100856

Elan Pharmaceuticals, Inc./Pharmacia
&
Upjohn Company

12/19/2002

**Examiner
Signature**

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

INFORMATION DISCLOSURE

(use as many sheets as necessary)

(use as many sheets as necessary)

Steel

2

of

3

Application Number	10/541,476
Filing Date	July 6, 2005
First Named Inventor	Craig A. Coburn et al.
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	21310YP

[illegible]Date
Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005